Analysts Set Personalis, Inc. (NASDAQ:PSNL) PT at $10.57

Personalis, Inc. (NASDAQ:PSNL) has been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $10.5714.

PSNL has been the topic of several recent research reports. HC Wainwright upped their price target on Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. BTIG Research upped their target price on shares of Personalis from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Morgan Stanley increased their price target on shares of Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Monday, December 1st. Guggenheim boosted their price objective on shares of Personalis from $6.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Finally, Lake Street Capital restated a “buy” rating and issued a $11.00 price objective on shares of Personalis in a report on Wednesday, November 5th.

Insider Activity at Personalis

In other Personalis news, CFO Aaron Tachibana sold 103,668 shares of the business’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total value of $1,117,541.04. Following the sale, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at approximately $1,772,857.24. The trade was a 38.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Christopher M. Hall sold 29,612 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $8.99, for a total value of $266,211.88. Following the completion of the sale, the chief executive officer directly owned 148,486 shares in the company, valued at approximately $1,334,889.14. This represents a 16.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 3.80% of the company’s stock.

Hedge Funds Weigh In On Personalis

Hedge funds have recently bought and sold shares of the company. Legal & General Group Plc purchased a new stake in Personalis during the 2nd quarter valued at about $30,000. Ameritas Investment Partners Inc. bought a new position in shares of Personalis in the second quarter worth approximately $34,000. BNP Paribas Financial Markets grew its holdings in shares of Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after buying an additional 5,177 shares during the last quarter. Alpha Wealth Funds LLC purchased a new stake in shares of Personalis during the second quarter valued at approximately $66,000. Finally, Farther Finance Advisors LLC bought a new stake in shares of Personalis during the third quarter valued at approximately $66,000. Institutional investors own 61.91% of the company’s stock.

Personalis Price Performance

Shares of PSNL opened at $7.97 on Friday. The company has a 50-day simple moving average of $8.91 and a two-hundred day simple moving average of $7.17. The firm has a market capitalization of $707.77 million, a PE ratio of -9.06 and a beta of 1.99. Personalis has a one year low of $2.83 and a one year high of $11.40.

Personalis (NASDAQ:PSNL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.04. The firm had revenue of $14.50 million during the quarter, compared to analyst estimates of $13.31 million. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%. Analysts expect that Personalis will post -1.4 EPS for the current fiscal year.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.